InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
-0.88%
)
US TECH 100
19,663.60
(
-2.26%
)
Dow Jones
39,753.75
(
0.08%
)
Brent Oil
85.11
(
0.07%
)
Bitcoin
57,456.60
(
-0.52%
)
Post# of 252578
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120030
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 247900

Thursday, 07/06/2023 1:31:06 PM

Thursday, July 06, 2023 1:31:06 PM

Post# of 252578
Re: Botox biosimilar

The latest material update I know of is in #msg-168817871, in which VTRS said FDA approval of the Botox biosimilar is targeted for 2026, with the 351(k) submission targeted for 2025.

RVNC’s most recent 10-Q filing (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000147929023000072/rvnc-20230331.htm#ia1ea4fa82c274a04af0ffacf37952862_28 p-8-9) includes some financial details of the collaboration.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up